There is also no evidence that ACE2 is upregulated in a dose-dependent manner in the course of such treatment, therefore, it seems that RAAS inhibitors should not be discontinued, especially bearing in mind that patients with COVID-19 and hypertension have a worse COVID-19 prognosis [136]. This evidence concerns the gene ACE2 and hypertensive disorder.